Annovis Bio: Positive Phase 2 Data Sets Stage for Phase 3 Trials

Sep. 2, 2021
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. Annovis has an ongoing Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients. Initial data, reported in the first half of 2021, showed ANVS401, the company’s lead candidate, improved speed and coordination scores and lowered levels of key inflammatory markers in PD patients and improved cognition in AD patients. Visit to learn more.

 Read More

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market